Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications:
- Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer.
- EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in hematological and solid tumors.
Founded by Truffle Capital, Evexta Bio has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and Merck KGaA (Darmstadt, Germany). The company is supported by seasoned management team, board of directors and medical advisory board.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 104 Bd De Sébastopol, Paris,île-De-France 75003,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- diaccurate.com
- Keywords
- Pharmaceuticals, Research & Development, oncology, biotech, KIF20A inhibitor, TRUFFLE CAPITAL, Rupitasertib, S6K AKT1/3 inhibitor, Diaccurate.
- HQ
- PARIS, Île-de-France
Evexta Bio Questions
Evexta Bio's website is diaccurate.com
Evexta Bio's LinkedIn profile is https://fr.linkedin.com/company/evextabio
Evexta Bio has
10 employees.
View email and phone details for 10
employees at Evexta Bio.
Evexta Bio's industry is
Biotechnology Research
Evexta Bio's top competitors are
Oncovita,
Affimed,
Abivax,
Biomunex Pharmaceuticals,
Aenitis Technologies,
Diogenx,
Inotrem,
Theravectys,
Cellectis,
Jalon Therapeutics.
Evexta Bio's categories are Biotechnology Research
Evexta Bio's founding year is 2012
